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Introduction
New technologies have led to options beyond the intra-aortic balloon pump (IABP) for mechanical circulatory support (MCS) in patients undergoing percutaneous coronary intervention (PCI) in the setting of cardiogenic shock or other high-risk settings. Although newer percutaneous ventricular assist devices have been shown to improve hemodynamic parameters with clinical outcomes comparable to IABP in small trials, 1-10 clear evidence of improved clinical outcomes with these newer devices is lacking. As a result, the optimal utilization of these new therapies remains unclear.
In addition to changing technologies for MCS, recent trial data questions the utility of IABP in improving patient outcomes. The IABP-SHOCK II trial 11 found no benefit of routine IABP use in patients with acute myocardial infarction complicated by cardiogenic shock. These findings may accentuate shifts to the use of newer mechanical circulatory support devices, despite a lack of clinical outcomes data. Furthermore, differences in procedural proficiency with newer support devices may lead to variations in clinical use. Although recent studies have suggested dramatic increases in the use of MCS, these studies did not specifically address contemporary clinical practice of MCS use in the setting of PCI or hospital-level variation in the use of MCS.
In this study, we sought to describe the overall utilization and temporal change in the patterns of utilization of standard (i.e. IABP) and newer mechanical support therapies across the United States for patients undergoing PCI in the setting of cardiogenic shock or high-risk PCI.
In addition, we evaluated site level variations in the use of MCS for coronary interventions in the setting of cardiogenic shock or high-risk PCI.
ABP in improving patient outcomes. The IABP-SHOCK II trial 11 found no bene e efi fi fit t t of of of r r rou ou outi ti tine ne ne ABP use in patients with acute myocardial infarction complicated by cardiogenic shock. These find din in ings gs gs m m may ay ay acc c cen en ntuate shifts to the use of newe we er r r m m mechanical circulato o ory ry ry support devices, Interventions, is the largest national registry of diagnostic cardiac catheterizations and percutaneous coronary interventions (PCI), with more than 1000 participating centers across the United States. The CathPCI ® registry has been described previously. 12, 13 The registry includes a standardized set of data elements which are defined by an NCDR committee. 14 
Mechanical circulatory support
Version 4 of the CathPCI ® data collection form, introduced in 2009, includes data capture on "other mechanical circulatory support device" referring to non-IABP mechanical circulatory support devices. 15 We used the term other mechanical circulatory support (O-MCS) to refer to non-IABP circulatory support devices (eg. TandemHeart ® , Impella ® , extracorporeal membrane oxygenation, etc) in this manuscript. Mechanical circulatory support (MCS) refers to the aggregate of IABP and O-MCS.
Study Population
We identified 76,544 patients that underwent PCI in the setting of cardiogenic shock at one of collected retrospectively or concurrently and represent consecutive patients treated ed ed a a at t t ea ea each ch ch participating institution and submitted to the CathPCI ® registry. Quality assurance is achieved hro oug ug ugh h h au au auto to toma m m ti ti tic c system validation, education a a and nd nd training of staff, re e epo po porting of completeness an an and d d random on-n-s s site e a a aud ud udit it itin in ing. g. g. In In Inst st stit it tut ut u io io ion ns are re re r r requ uir r red t t to o o me me mee e et N N NDC DC CR R Ru q a ality y y cr cr crit it iter er eria ia ia f f for o or e epo po port rt r ing in n o o ord r e er e t t to a ac ch hi h eve e e in n ncl c c us s sio io ion. n. .
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1,429 NCDR CathPCI ® participating hospitals from July 1st, 2009 to September 30th, 2013.
Cardiogenic shock was defined as specified in CathPCI ® . This is a sustained episode (>30 minutes) of systolic blood pressure <90 mmHg and/or cardiac index <2.2 L/min/m2 determined to be secondary to cardiac dysfunction, and/or the requirement for parenteral inotropic or vasopressor agents or support (eg. IABP, extracorporeal circulation, ventricular assist devices) to maintain blood pressure and cardiac index above those specified levels. We excluded 70 (0.1%) patients with missing data regarding use of MCS, resulting in an analytic cohort that included 76,474 patients across 1,429 hospitals who underwent PCI in the setting of cardiogenic shock. In the description of hospital-level use of MCS, we excluded 924 patients at 193 (13.5%) hospitals with fewer than 10 PCIs during the study period to avoid inflation of variance due to small numbers.
In a secondary analysis, we assessed the use of these devices in the setting of high-risk PCI using the definition applied in prior CathPCI ® studies. 16, 17 High risk PCI was defined as at least one of the following: (1) unprotected left main artery as the target vessel (without bypass grafting), (2) severely depressed left ventricular function (ejection fraction <30%), (3) STelevation myocardial infarction (STEMI) or (4) cardiogenic shock. We identified 579,413 patients at 1,461 hospitals undergoing high-risk PCI. We excluded 364 (0.1%) patients for missing data on the use of MCS, leaving 579,079 patients at 1,461 hospitals in this secondary cohort.
Statistical Analysis
We compared patient demographics, risk factors and comorbid conditions in addition to procedural characteristics, including timing of procedures, findings on coronary angiography, PCI procedural data and peri-procedural medication use by type of MCS (none, IABP alone, O-with fewer than 10 PCIs during the study period to avoid inflation of variance due ue e t t to o o sm sm smal al all l l numbers.
In In In a a a s s sec e e on on nda d d ry analysis, we assessed the u u use se se of these devices in n t t the h h setting of high-risk P P PCI I I using the de de def fin niti ti tion on on a a app pp ppli li lied ed ed i i in n n p p prio io ior Ca ath t t P P PCI a a a ® ® s s studi di die e es. 16, 16, 16, 17 Hi Hi Hi h gh gh r r ris is isk k PC C CI I I wa wa was s s de de d fi fi fin ne n d d d as as as a a at t t e ea as a t t t on o e of f t t the h h f f fol l llow w win ng n : (1 1 1) ) un u u p p pro ro rotec c cte ed e l lef ef eft t t ma ain n n ar r rte er ery y a a as the he he ta a arge g g t v vess s sel el e ( ( (with th ho o out by by bypas ss gr gr graf af afti ti ting ng ng) ) ), ( ( (2) 2) 2) s s sev e ever er erel el ely de de depr pr pres es esse se sed d d le le left ft ft ven en entr tr tric ic icul l ular ar ar f f fun n unct ct ctio io ion n n (e (e (eje je ject ct ctio io ion n n fr fr frac ac acti ti tion on on < < <30 30 30%) %) %), characteristics by type of MCS was statistically significant for most characteristics given our sample size, but the majority of differences were clinically modest ( Most procedural characteristics by type of MCS were statistically significant given our sample size, however, largely similar and clinically modest ( Table 2) . Notably, patients receiving MCS were also more likely to be in cardiogenic shock at the start of PCI in comparison to those receiving no mechanical support (88% vs. 75%, p<0.001). IABP was placed at the start of the procedure in 9% of cases, during the procedure pre-PCI in 34% and after starting PCI in 57%. In comparison, O-MCS was placed at the start of the procedure in 40%, during the procedure but prior to PCI in 37% and after starting PCI in 23%. When both O-MCS+IABP were used, an MCS device was placed at the start of the procedure in 45%, during the procedure pre-PCI in 26% and after starting PCI in 29%. Salvage PCI, defined in version 4 of the CathPCI ® data collection form 15 
Discussion
We sought to describe the overall utilization, temporal trends, and hospital-level variation in the use of MCS for PCI in the setting of cardiogenic shock or high-risk features. In this large, national registry of more than 75,000 patients undergoing PCI in the setting of cardiogenic shock, 46% underwent PCI with MCS with 39% receiving IABP only, 3.5% supported by O-MCS and 3.6% by both IABP and O-MCS. There was a declining trend in IABP use over the study period with no change in the rate of use of O-MCS. Despite a decreasing trend in IABP use, the rate of decline did not change following publication of the IABP-SHOCK II trial which found no benefit of IABP in the setting of MI. 11 We observed significant hospital level and geographic variation in the use of IABP and O-MCS, with very few hospitals employing O-MCS technologies. Our findings were similar for MCS use in high-risk PCI.
Recent studies have emphasized potential hemodynamic benefits of newer mechanical support devices. [1] [2] [3] [4] [5] [6] Small clinical trials and case studies have suggested mixed results with regards to patient outcomes compared to IABP use. [7] [8] [9] [10] In addition, recent trial data questions the routine use of IABP therapy to improve patient outcomes. 11 A recent study suggests a dramatic increase in the rate of short term use of MCS over the past decade. 19 However, findings from this study are derived from the National Inpatient Sample which is composed predominantly of urban, teaching hospitals 20 We found patients receiving newer MCS therapies had more comorbidities, were more likely to have left ventricular systolic dysfunction or heart failure and present with cardiac arrest or ongoing signs of cardiogenic shock at the start of PCI compared to patients treated without MCS or with IABP use alone. The greater severity of patient comorbidities and presenting illness among patients receiving newer MCS therapies may reflect operator selection of novel percutaneous support devices among sicker patients.
Since 2009, we found that the rate of IABP use in PCI during cardiogenic shock has been declining at a small, but statistically significant rate. Recent trial data has called into question the role of IABP therapy in acute MI complicated by cardiogenic shock compared to medical therapy alone. 11 In the immediate period following publication of this trial, we saw a significant 3.2% total decline in IABP use. However, following this immediate drop, the post-publication quarterly rate of decline did not differ significantly from the pre-publication trend in IABP use.
The lack of a more pronounced decline in IABP use may reflect the persistence of IABP as a class IIa indication (weight of evidence/opinion is in favor of usefulness or efficacy) for ST elevation MI complicated by cardiogenic shock in the 2013 ACC/AHA STEMI guidelines. 17 Small, randomized clinical trials have attempted to evaluate the efficacy of the newer MCS systems versus conventional therapy with IABP in the treatment of cardiogenic shock. [7] [8] [9] [10] These trials have demonstrated better hemodynamic profiles with newer circulatory support devices without translation into improvement in mortality rates. Despite these emerging data on newer MCS therapies, we found no significant increase in the use O-MCS technologies to offset the observed decline in IABP use. This lack of O-MCS uptake in the cardiology community declining at a small, but statistically significant rate. Recent trial data has called in in into to toue ue uest st stio io ion n n he role of IABP therapy in acute MI complicated by cardiogenic shock compared to medical her rap ap apy y y al al alon on one. e e 11 In In In the immediate period follow win in ing g g publication of this tr tr tria ia ial, we saw a significant Our work shows significant site and geographic variation in the use of IABP and O-MCS.
Prior work has described considerable hospital level variation in IABP use for patients undergoing high-risk PCI as well as coronary artery bypass grafting. 17, 21 In addition to observing broad facility-level variation in IABP use during PCI in the setting of cardiogenic shock, our study demonstrates use of O-MCS is clustered at a small number of hospitals and these hospitals were more likely to be teaching hospitals. In a prior study of MCS use in the National Inpatient Sample, teaching hospitals represented nearly 80% of the study sample. 19 The larger contribution of teaching hospitals to the National Inpatient Sample may explain the substantial increase in O-MCS reported in this study compared to our findings from the NCDR CathPCI ® data. In a secondary analysis, we examined the rate of use of IAPB and O-MCS for high-risk PCI. Through the study period, we discovered a small temporal decline in IABP use and unchanged O-MCS use in the setting of high-risk PCI. Similar to prior studies, we observed broad hospital level variation in the predicted probability of IABP use in high-risk PCI. 17 As was observed for PCI in the setting of cardiogenic shock, O-MCS use was clustered at few hospitals.
Prior publications question the routine use of IABP [22] [23] [24] in contrast to recent data suggesting clinical benefit of IABP use in the setting high-risk PCI. 25 
